Shares in Wave Life Sciences Ltd. (NASDAQ: WVE) were unchanged Wednesday. The Cambridge, Mass.-based concern, a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the second quarter ended June 30, 2025.
Wednesday morning’s news release reported cash and cash equivalents were $208.5 million as of June 30, 2025, compared to $302.1 million as of December 31, 2024.
Wave expects that its current cash and cash equivalents will be sufficient to fund operations into 2027. Potential future milestones and other payments to Wave under its GSK collaboration are not included in its cash runway.
Revenue recognized was $8.7 million for the second quarter of 2025 as compared to $19.7 million in the prior year quarter.
Research and development expenses were $43.5 million in the second quarter of 2025 as compared to $40.4 million in the same period in 2024.
General and administrative expenses were $18.0 million in the second quarter 2025 as compared to $14.3 million in the same period in 2024.
Net loss was $50.5 million for the second quarter of 2025 as compared to $32.9 million in the prior year quarter.
WVE shares gathered a penny to $8.33
